The rationale for combination therapy

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Dyslipidemia management is key for coronary heart disease (CHD) patients.
• Low-density lipoprotein (LDL) cholesterol reduction is the primary therapeutic goal per Adult Treatment Panel III guidelines.
• Low high-density lipoprotein (HDL) cholesterol and elevated triglycerides are significant CHD risk factors.

Purpose of the Study:

• To review the rationale for using combination lipid-altering therapy in dyslipidemia.
• To highlight effective management strategies for dyslipidemia using combination therapies.
• To emphasize the importance of addressing multiple lipid parameters beyond LDL cholesterol.

Main Methods:

• Review of existing literature and clinical guidelines on dyslipidemia treatment.
• Analysis of the benefits of LDL cholesterol reduction on CHD events and mortality.
• Examination of the role of combination therapy involving statins with other lipid-lowering agents.

Main Results:

• Combination therapy is increasingly vital for effective dyslipidemia management in CHD.
• Targeting LDL cholesterol is primary, but addressing HDL and triglycerides offers additional benefits.
• Statins combined with niacin, fibric acid derivatives, bile acid resins, or cholesterol absorption inhibitors are common strategies.

Conclusions:

• Combination lipid-altering therapy is essential for comprehensive dyslipidemia treatment.
• Aggressive management strategies are often necessary, frequently involving multiple drug classes.
• Addressing aberrant lipoprotein subclasses and triglyceride levels improves outcomes in mixed dyslipidemias.